FGF-23 Associates with Death, Cardiovascular Events, and Initiation of Chronic Dialysis
Authors:
- Alfred K. CheungACAlfred K. Cheung
- James S. KaufmanJKJames S. Kaufman
- Tom GreeneTGTom Greene
- William L. RobertsWRWilliam L. Roberts
- Gerard SmitsGSGerard Smits
- Michel ChoncholMCMichel Chonchol
- the HOST InvestigatorsTIthe HOST Investigators
Top Cited Papers
- 1 October 2011
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 22 (10) , 1913-1922
Abstract
Concentrations of the phosphate-regulating hormone fibroblast growth factor-23 (FGF-23) are elevated in patients with chronic kidney disease (CKD), but whether higher plasma FGF-23 concentrations associate with all-cause mortality, cardiovascular events, or initiation of chronic dialysis is not completely understood. Here, we measured FGF-23 concentration in stored plasma samples from 1099 patients with advanced CKD who participated in The Homocysteine in Kidney and End Stage Renal Disease study. Mean serum phosphorus concentration was 4.3 mg/dl, median FGF-23 concentration was 392 RU/ml, and mean GFR was 18 ml/min/1.73 m2. During a median follow-up of 2.9 yr, 453 (41%) patients died from any cause, 215 (20%) had a cardiovascular event, and 615 (56%) initiated chronic dialysis. Compared with the lowest quartile of FGF-23, each subsequent quartile associated with a progressively higher risk for death, adjusted for confounders (HR [95% CI] of 1.24 [0.91 to 1.69], 1.76 [1.28 to 2.44], and 2.17 [1.56 to 3.08] for the second through fourth quartiles, respectively). In addition, compared with the lowest quartile, the two highest quartiles of FGF-23 also associated with a significantly elevated risk for cardiovascular events and initiation of chronic dialysis. In conclusion, in advanced CKD, FGF-23 strongly and independently associates with all-cause mortality, cardiovascular events, and initiation of chronic dialysis.Keywords
This publication has 36 references indexed in Scilit:
- Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the communityAtherosclerosis, 2009
- Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney DiseaseCirculation, 2009
- Phosphorus Binders and Survival on HemodialysisJournal of the American Society of Nephrology, 2009
- Fibroblast Growth Factor 23 and Mortality among Patients Undergoing HemodialysisNew England Journal of Medicine, 2008
- Postprandial Mineral Metabolism and Secondary Hyperparathyroidism in Early CKDJournal of the American Society of Nephrology, 2008
- Prevalence of Chronic Kidney Disease in the United StatesJAMA, 2007
- Cardiovascular Mortality Risk in Chronic Kidney DiseaseJAMA, 2005
- Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and HospitalizationNew England Journal of Medicine, 2004
- Longitudinal Follow-up and Outcomes Among a Population With Chronic Kidney Disease in a Large Managed Care OrganizationArchives of internal medicine (1960), 2004
- Assessing renal function from creatinine measurements in adults with chronic renal failureAmerican Journal of Kidney Diseases, 1998